Compare Stocks → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKUOTCMKTS:BSTGNASDAQ:EFTRNASDAQ:IMV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkumin$0.18$0.12▼$1.90$26.32M-0.721.38 million shs8.54 million shsBSTGBiostage$4.45$4.45$4.45▼$4.45$61.78M-1.021,847 shsN/AEFTReFFECTOR Therapeutics$1.81-2.2%$9.80$1.60▼$37.00$6.68M0.52324,703 shs9,481 shsIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%-53.44%BSTGBiostage0.00%0.00%0.00%0.00%-25.83%EFTReFFECTOR Therapeutics-4.64%-2.12%-86.56%-79.63%-80.44%IMVIMV0.00%0.00%0.00%0.00%+1.54%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUAkuminN/AN/AN/AN/AN/AN/AN/AN/ABSTGBiostageN/AN/AN/AN/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics1.0876 of 5 stars3.52.00.00.00.60.80.6IMVIMVN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUAkumin1.50Reduce$0.25∞ UpsideBSTGBiostageN/AN/AN/AN/AEFTReFFECTOR Therapeutics3.00Buy$24.001,225.97% UpsideIMVIMV2.00HoldN/AN/ACurrent Analyst RatingsLatest AKU, EFTR, IMV, and BSTG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024EFTReFFECTOR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.002/6/2024EFTReFFECTOR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUAkumin$749.63M0.00N/AN/A$1.24 per share0.00BSTGBiostageN/AN/AN/AN/A($0.26) per shareN/AEFTReFFECTOR Therapeutics$3.55M1.88N/AN/A($1.94) per share-0.93IMVIMV$330K0.00N/AN/A($0.69) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUAkumin-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/ABSTGBiostage-$6.07M-$0.58N/A∞N/AN/AN/A-174.43%N/AEFTReFFECTOR Therapeutics-$35.81M-$16.92N/AN/AN/AN/AN/A-160.00%5/14/2024 (Estimated)IMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/ALatest AKU, EFTR, IMV, and BSTG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2024Q4 2023EFTReFFECTOR Therapeutics-$2.73-$3.42-$0.69-$3.42N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUAkuminN/AN/AN/AN/AN/ABSTGBiostageN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUAkumin17.020.990.99BSTGBiostageN/A2.732.73EFTReFFECTOR TherapeuticsN/A0.770.77IMVIMVN/A2.932.93OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUAkumin36.10%BSTGBiostageN/AEFTReFFECTOR Therapeutics57.67%IMVIMV15.37%Insider OwnershipCompanyInsider OwnershipAKUAkumin20.51%BSTGBiostage15.30%EFTReFFECTOR Therapeutics8.40%IMVIMV0.33%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKUAkumin3,63191.17 million72.47 millionNot OptionableBSTGBiostage713.88 million11.76 millionNot OptionableEFTReFFECTOR Therapeutics143.69 million3.38 millionOptionableIMVIMV9711.71 million11.67 millionOptionableAKU, EFTR, IMV, and BSTG HeadlinesSourceHeadlinePhilippines growth slows sharply in Marchjust-auto.com - April 23 at 9:42 AMWhy it’s likely Toyota will revive the ‘Stallion’ badge in SAcars.co.za - April 18 at 1:41 AMGWC introduces vision picking technology in Qatarzawya.com - April 16 at 8:13 AMHolliday's first hit helps the Orioles rally to a 6-4 win over the Brewers and avoid a sweepwsbtv.com - April 14 at 6:46 PMGolden Bachelor news: Gerry and Theresa break up, but still love each othermsn.com - April 13 at 9:37 AMThe future Toyota EVs that could trump Teslajust-auto.com - April 9 at 7:56 PMThe Pros And Cons Of Owning Toyota's $13,000 Pickup Truckmsn.com - April 7 at 10:44 AMBangkok 2024: Toyota Hilux Champ – workhorse truck; SWB and LWB; petrol/diesel; 5MT/6AT; from RM59kpaultan.org - April 5 at 7:24 AMToyota's Wacky Front and Rear Sliding Door Crossover Van Comes to Life Digitallyautoevolution.com - April 4 at 7:13 AMWhy are there so many cars in Omaha without license plates?msn.com - April 3 at 7:17 PMToyota's stout, crazy-modular $12K tiny truck makes enticing mini-RVnewatlas.com - April 3 at 7:17 PMVirginia Tech hires Marquette's Megan Duffy as new coachmsn.com - April 3 at 2:17 PMCalciMedica, Inc.: CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updatesfinanznachrichten.de - March 28 at 11:06 AMPhilippines sales up in February 2024msn.com - March 27 at 6:30 PMPhilippines sales rise in Februaryjust-auto.com - March 27 at 8:30 AMAn Electric Toyota Hilux Is Reportedly Coming by 2025msn.com - March 26 at 2:02 PMThe New FJ Cruiser Could Use Toyota's $13,000 Truck Platformmsn.com - March 26 at 9:01 AMAsian hornet may have become established in UK, sighting suggeststheguardian.com - March 25 at 5:59 PMNew ultrasound software designed to help vets give better bovine breeding advicevetsurgeon.org - March 25 at 5:59 PMToyota FJ Cruiser reboot rumored to sit on Hilux Champ chassisautoblog.com - March 25 at 12:57 PMBioVaxys Technology Corp.: BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENTfinanznachrichten.de - March 22 at 7:21 PM2024 Toyota Zenix Hybrid Reviewautodeal.com.ph - March 21 at 8:53 PMBioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Updatefinance.yahoo.com - March 21 at 8:53 PMHyundai ST-1 is a commercial EV with Staria faceautoindustriya.com - March 18 at 2:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkuminNASDAQ:AKUAkumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.BiostageOTCMKTS:BSTGBiostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.eFFECTOR TherapeuticsNASDAQ:EFTReFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.IMVNASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.